Magnus Franzen

Helping pharma improve patients' lives and bring more value to customers using integrated care and innovative technology. Work @PAConsulting, tweets are my own.

[Magnus Franzen @MagnusPAFranzen]

@FlySWISS I'm not getting any help from your service centre. You cancelled my flight and won't even recognise that it happened.
Can you please contact me to sort this out asap?
#horriblecustomerexperience
#unacceptable

[Magnus Franzen @MagnusPAFranzen]

New article from Hans-Peter Frank, Diane Bell and myself on pharma's opportunity in exploring new models of care

[Magnus Franzen @MagnusPAFranzen]

I'm attending @Reuters IMPACT - the virtual forum uniting global leaders to drive sustainable climate action, October 4-7, 2021. Registration is free for a limited time only, register now #ReutersIMPACT https://t.co/syZAGsCqUX

[Magnus Franzen @MagnusPAFranzen]

“The implications of #darkdata [for pharma] are profound”. @PA_Consulting’s @SR_disrupt, @MartinKnoebel, & Michael Carver in @FWPharma. Read now https://t.co/uAweIj5uZc

[Reuters Events Pharma @RE_Pharma]

Where is pharma's value? A new thought-provoking webinar just launched. Sign up for free: https://t.co/Nu3KevDpJk #pharma

[Magnus Franzen @MagnusPAFranzen]

#biosimilar companies should develop specific commercial strategies to win beyond regulatory approval #pharma https://t.co/US48cWdWEU

[Magnus Franzen @MagnusPAFranzen]

6 #biosimilar business archetypes & how they’re likely to evolve >> https://t.co/lvOg3p7r7F [NEW REPORT] #pharma #amgen #sandoz #Pfizer

[Magnus Franzen @MagnusPAFranzen]

3 challenges shaping the #biosimilars market >> https://t.co/lvOg3oPQg7 [NEW REPORT] #pharma

[Magnus Franzen @MagnusPAFranzen]

What is the right commercial model for the complex #biosimilars market? >> https://t.co/lvOg3p7r7F [NEW REPORT] #pharma

[Magnus Franzen @MagnusPAFranzen]

@biosimilarz Thought you might find this interesting: #Biosimilar commercial strategy new report: https://t.co/lvOg3p7r7F

[Magnus Franzen @MagnusPAFranzen]

#Biosimilars: how to differentiate & survive the cost of entry >> https://t.co/lvOg3oPQg7 [FREE REPORT] #pharma

[Magnus Franzen @MagnusPAFranzen]

"Biosimilar commercial strategies [FREE REPORT]" https://t.co/jWZK4Wgx4q by @MagnusPAFranzen on @LinkedIn

[Magnus Franzen @MagnusPAFranzen]

@ThreeUKSupport Like I said... the worst company ever just spent even more time with your social media support to get told you can't help!!!

[Magnus Franzen @MagnusPAFranzen]

@ThreeUKSupport - no i was told I had to raise the complaint myself once the phone had arrived - which of course will now be 1 day too late

[Magnus Franzen @MagnusPAFranzen]

@ThreeUKSupport So first you told me my credit check was declined, finally got that sorted, but unable to get the offer I was promised.

[Magnus Franzen @MagnusPAFranzen]

@ThreeUKSupport you're such a useless company!! Your stupid sales people just stole 1h of my life without being able to sell me a phone!!!

[Magnus Franzen @MagnusPAFranzen]

@TfLBusAlerts your bus drivers have no decency!! Not even stopping to pick up passengers with an empty bus! 148 @ London Hilton.

[Magnus Franzen @MagnusPAFranzen]

Will a fee-for-outcome mindset trigger new, disruptive healthcare financing models ? https://t.co/x1tBC1610K

[Magnus Franzen @MagnusPAFranzen]

My New Whitepaper: Multichannel Marketing & Pharma Reps https://t.co/iI4IM1CTd8

[Magnus Franzen @MagnusPAFranzen]

Management Today https://t.co/B6TMMfAuUG